Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Truqap (capivasertib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca, Otsuka

Drug class:

AKT inhibitor

Related drugs:

‹

›

PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
AKT1 mutation + HR positive	HER2 Negative Breast Cancer	AKT1 mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PTEN mutation + HR positive	HER2 Negative Breast Cancer	PTEN mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PTEN deletion + ER positive	HER2 Negative Breast Cancer	PTEN deletion + ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
AKT1 mutation + ER positive	HER2 Negative Breast Cancer	AKT1 mutation + ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
AKT1 mutation + ER positive	Breast Cancer	AKT1 mutation + ER positive	Breast Cancer	capivasertib Sensitive: C1 - Off-label capivasertib Sensitive : C1	capivasertib Sensitive: C1 - Off-label capivasertib Sensitive : C1
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2
PIK3CA mutation	Gastric Cancer	PIK3CA mutation	Gastric Cancer	capivasertib Sensitive: C2 – Inclusion Criteria capivasertib Sensitive : C2	capivasertib Sensitive: C2 – Inclusion Criteria capivasertib Sensitive : C2
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2
AKT1 E17K	Salivary Gland Cancer	AKT1 E17K	Salivary Gland Cancer	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3